Table 2 PANSS scores, HAMD score, CGI-S and PSP at baseline, week 4, week 8, week 12 and week 24 in first episode drug-naïve patients with schizophrenia treated with risperidone with sertraline (RS) group and risperidone monotherapy (control) group (mean ± SD)
Baseline (n = 230) | Week 4 (n = 230) | Week 8 (n = 230) | Week 12 (n = 230) | Week 24 (n = 230) | Group (p value)a | Group × Time F(p value)a | |
|---|---|---|---|---|---|---|---|
PANSS positive subscore | 5.1 (0.03) | 8.2 (0.002) | |||||
Control group | 24.9 ± 6.2 | 17.6 ± 5.1 | 14.8 ± 5.1 | 12.5 ± 5.1 | 11.1 ± 5.4 | ||
RS group | 23.9 ± 6.3 | 17.9 ± 5.1 | 13.4 ± 4.3 | 10.5 ± 3.9 | 9.1 ± 3.7 | ||
PANSS negative subscore | 25.0 (< 0.001) | 78.0 (< 0.001) | |||||
Control group | 28.9 ± 6.1 | 24.2 ± 7.1 | 21.5 ± 6.6 | 18.6 ± 6.0 | 15.8 ± 5.2 | ||
RS group | 30.2 ± 7.2 | 24.0 ± 7.2 | 19.5 ± 6.8 | 15.5 ± 4.8 | 11.0 ± 2.4 | ||
PANSS general psychological subscore | 9.6 (0.002) | 24.2 (< 0.001) | |||||
Control group | 58.3 ± 8.8 | 48.0 ± 9.4 | 40.9 ± 9.5 | 31.0 ± 9.1 | 27.6 ± 10.0 | ||
RS group | 59.9 ± 8.8 | 48.0 ± 8.9 | 37.5 ± 9.2 | 25.1 ± 5.8 | 22.6 ± 6.1 | ||
PANSS total score | 19.8 (0.001) | 39.2 (< 0.001) | |||||
Control group | 112.7 ± 12.8 | 92.0 ± 13.1 | 75.8 ± 13.7 | 56.3 ± 8.5 | 46.3 ± 6.2 | ||
RS group | 114.1 ± 13.6 | 90.4 ± 13.7 | 69.6 ± 14.0 | 49.2 ± 6.1 | 40.4 ± 3.1 | ||
CGI-S score | 30.9 (< 0.001) | 42.2 (< 0.001) | |||||
Control group | 5.9 ± 0.7 | 4.8 ± 0.4 | 4.0 ± 0.5 | 3.6 ± 0.7 | 3.2 ± 1.0 | ||
RS group | 5.8 ± 0.6 | 4.8 ± 0.6 | 3.9 ± 0.6 | 3.0 ± 0.7 | 2.2 ± 1.0 | ||
HAMD total score | 85.1 (< 0.001) | 90.5 (< 0.001) | |||||
Control group | 24.3 ± 4.8 | 19.0 ± 5.3 | 15.3 ± 4.6 | 12.5 ± 4.1 | 9.7 ± 4.6 | ||
RS group | 24.8 ± 5.7 | 18.5 ± 5.4 | 11.0 ± 3.2 | 6.9 ± 2.8 | 4.2 ± 3.3 | ||
PSP total score | 34.2 (< 0.001) | 47.7 (< 0.001) | |||||
Control group | 34.9 ± 5.2 | 44.6 ± 3.7 | 58.0 ± 8.9 | 64.8 ± 12.4 | 70.1 ± 15.2 | ||
RS group | 34.2 ± 3.6 | 45.9 ± 4.9 | 62.2 ± 7.3 | 74.1 ± 9.6 | 83.2 ± 11.3 | ||